AMERICAN COLLEGE OF SURGEONS ONCOLOGY GROUP

美国外科学院肿瘤学组

• 批准号: 6604337
• 负责人: SAMUEL A WELLS
• 金额: $ 813.91万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-05-15 至 2005-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6604337
• 关键词: biomarker; breast neoplasms; cancer prevention; cancer risk; clinical research; clinical trials; combination cancer therapy; cooperative study; esophagus neoplasm; human subject; human therapy evaluation; intestine neoplasm; lung neoplasms; melanoma; metastasis; neoplasm /cancer chemotherapy; neoplasm /cancer classification /staging; neoplasm /cancer diagnosis; neoplasm /cancer genetics; neoplasm /cancer immunotherapy; neoplasm /cancer palliative treatment; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; retinoblastoma

The American College of Surgeons Oncology Group (ACOSOG) was recently established to define the role of surgical therapies in patients with malignant solid tumors. The ACOSOG incorporates general and specialty surgical oncologists, and non-surgical oncologists, in academic medical centers and community practice throughout the United States of America and in foreign countries. This surgical group is important to the oncological community because of the primary role of surgery in the treatment of the cancer patient. Also the interrelationship of the ACOSOG with the American College of Surgeons (ACOS) provides a unique opportunity to utilize evidenced based medicine to educate large number of surgeons in the standard of care for the cancer patient. ACOSOG trials will evaluate several areas of surgical and basic oncology. The most important are: a) new and existing operative procedures; b) new technology and devices, c) diagnostic molecular markers and therapeutic biologic agents, d) radiographic imaging procedures, and e) interventional therapy in patients demonstrated to have a genetic predisposition for cancer. ACOSOG will also perform multimodality therapeutic trials in patients with certain solid tumors that are less accessible to other cooperative groups because they are uncommon and are treated primarily by surgical resection. ACOSOG will participate in Intergroup studies when the Group's resources and access to surgical patients can substantially enhance accrual to those trials. ACOSOG benefits from its strong relationship with the American College of Surgeons (ACS), the largest organization of surgeons in the world with broad geographic membership including general and specialty surgeons in both academic and private practice. This broad membership also positions ACOSOG to offer clinical trials to women, minorities and underserved populations. In addition, for purposes of institutional auditing and physician education, ACOSOG will interact closely with the Commission on Cancer (COC) of the ACS which has a large staff serving the Cancer Programs of almost 1500 approved hospitals across North America. ACOSOG is committed to lowering cancer incidence and mortality through innovative clinical trials that allow broad physician and patient participation.

美国外科医生学会肿瘤学组 (ACOSOG) 最近 旨在明确手术治疗在患有以下疾病的患者中的作用： 恶性实体瘤。 ACOSOG 包含通用和专业 学术医学领域的外科肿瘤学家和非外科肿瘤学家 遍布美国和美国的中心和社区实践 外国。 该手术组对肿瘤学很重要 社区因为手术在治疗中的主要作用 癌症患者。 还有 ACOSOG 与美国的相互关系 外科医生学院（ACOS）提供了一个独特的机会来利用证据 以医学为基础，对大量外科医生进行护理标准方面的教育 癌症患者。 ACOSOG 试验将评估外科和基础肿瘤学的多个领域。 这 最重要的是： a) 新的和现有的操作程序； b) 新的 技术和设备，c) 诊断分子标记和治疗 生物制剂，d) 放射成像程序，以及 e) 介入治疗 治疗已证明具有癌症遗传倾向的患者。 ACOSOG 还将对患有以下疾病的患者进行多模式治疗试验 其他合作团体较难接触到的某些实体瘤 因为它们并不常见，并且主要通过手术切除来治疗。 当集团的资源和资源充足时，ACOSOG 将参与集团间研究 接触手术患者可以大大提高这些试验的效果。 ACOSOG 受益于与美国大学的密切关系 外科医生协会（ACS）是世界上最大的外科医生组织，拥有广泛的 地理成员资格包括两个领域的普通外科医生和专科外科医生 学术和私人实践。 如此广泛的成员资格也使 ACOSOG 能够 为女性、少数族裔和服务不足的人群提供临床试验。 在 此外，出于机构审计和医生教育的目的， ACOSOG 将与 ACS 癌症委员会 (COC) 密切互动 拥有大量工作人员，为近 1500 名已批准的癌症项目提供服务 北美各地的医院。 ACOSOG 致力于通过以下方式降低癌症发病率和死亡率 创新的临床试验让广大医生和患者能够 参与。